A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression
Science Immunology · 10.05.2024 · 9 (95)
DOI: 10.1126/sciimmunol.adi4191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 10.05.2024. Verfasst von Michael P Plebanek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Lactic Acid, Melanoma, Signal Transduction. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Conventional dendritic cells (DCs) are essential mediators of antitumor immunity. As a result, cancers have developed poorly understood mechanisms to render DCs dysfunctional within the tumor microenvironment (TME). After identification of CD63 as a specific surface marker, we demonstrate that mature regulatory DCs (mregDCs) migrate to tumor-draining lymph node tissues and suppress DC antigen cross-presentation in trans while promoting T helper 2 and regulatory T cell differentiation. Transcriptional and metabolic studies showed that mregDC functionality is dependent on the mevalonate biosynthetic pathway and its master transcription factor, SREBP2. We found that melanoma-derived lactate activates SREBP2 in tumor DCs and drives conventional DC transformation into mregDCs via homeostatic or tolerogenic maturation. DC-specific genetic silencing and pharmacologic inhibition of SREBP2 promoted antitumor CD8 + T cell activation and suppressed melanoma progression. CD63 + mregDCs were found to reside within the lymph nodes of several preclinical tumor models and in the sentinel lymph nodes of patients with melanoma. Collectively, this work suggests that a tumor lactate-stimulated SREBP2-dependent program promotes CD63 + mregDC development and function while serving as a promising therapeutic target for overcoming immune tolerance in the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
- Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27708, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Surgery, Division of Surgical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
ORCID-Profile: Michael P Plebanek, Y-Van Nguyen, Nicholas C DeVito, Xueying Wang, Alisha Holtzhausen, Georgia M Beasley, Balamayooran Theivanthiran, Brent A Hanks
Förderung
- NCI NIH HHS
Zitieren
APA
Plebanek, M. P., Xue, Y., Nguyen, Y. V., DeVito, N. C., Wang, X., Holtzhausen, A., Beasley, G. M., Theivanthiran, B., & Hanks, B. A. (2024). A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Science Immunology, 9(95). https://doi.org/10.1126/sciimmunol.adi4191
Vancouver
Plebanek MP, Xue Y, Nguyen YV, DeVito NC, Wang X, Holtzhausen A, et al. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Science Immunology. 2024;9(95). doi:10.1126/sciimmunol.adi4191
BibTeX
@article{Plebanek2024,
author = {Plebanek, Michael P and Xue, Yue and Nguyen, Y-Van and DeVito, Nicholas C and Wang, Xueying and Holtzhausen, Alisha and Beasley, Georgia M and Theivanthiran, Balamayooran and Hanks, Brent A},
title = {A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression},
journal = {Science Immunology},
year = {2024},
volume = {9},
number = {95},
doi = {10.1126/sciimmunol.adi4191}
}
EUVIMED